Marco Quarta
Co-Founder, Chief Scientific Officer & Board Member Rubedo Life Sciences Inc
Marco Quarta, PhD, is Co-Founder and Chief Scientific Officer of Rubedo Life Sciences, where he pioneers senescence-targeting therapeutics for age-related diseases, including chronic respiratory conditions. With a background in aging, stem cell biology, and regenerative medicine from Stanford University, Marco previously led translational programs at the VA Palo Alto’s Center for Tissue Regeneration and Stanford University School of Medicine. His work focuses on leveraging immune surveillance and tissue rejuvenation strategies to restore lung function and combat fibrosis. He holds over 35 publications and patents and serves on multiple advisory boards advancing innovation in longevity and respiratory health.
Seminars
Panel Discussion Points:
- Is complete lung regeneration achievable, or is the primary goal to halt further tissue damage and improve function in IPF?
- What are the potential risks (e.g., tumorigenesis, stem cell activation) versus the promising benefits of regenerative therapies?
- Which biomarkers are crucial to track and validate the success of regenerative approaches in IPF?
- How can insights from tissue engineering, oncology, and other regenerative medicine areas inform and advance lung regeneration therapies for IPF?
- Which regenerative approaches are showing real potential for recovery versus those focusing on disease modification in the IPF treatment landscape?
